Andrea Schuster
Overview
Explore the profile of Andrea Schuster including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
99
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Westhoff M, Schuler-Ortoli M, Zerrinius D, Hadzalic A, Schuster A, Strobel H, et al.
Pharmaceuticals (Basel)
. 2022 Jan;
15(1).
PMID: 35056150
Medulloblastoma (MB) is the most common solid tumour in children and, despite current treatment with a rather aggressive combination therapy, accounts for 10% of all deaths associated with paediatric cancer....
2.
Selvasaravanan K, Wiederspohn N, Hadzalic A, Strobel H, Payer C, Schuster A, et al.
Sci Rep
. 2020 May;
10(1):7401.
PMID: 32366879
Glioblastoma (GB) is a highly aggressive, difficult to treat brain tumour. Successful treatment, consisting of maximal safe tumour de-bulking, followed by radiotherapy and treatment with the alkylating agent Temozolomide (TMZ),...
3.
Probsting M, Schenke D, Hossain R, Hader C, Thurau T, Wighardt L, et al.
Plant Biotechnol J
. 2020 May;
18(11):2328-2344.
PMID: 32358986
Brassica napus is highly susceptible towards Verticillium longisporum (Vl43) with no effective genetic resistance. It is believed that the fungus reprogrammes plant physiological processes by up-regulation of so-called susceptibility factors...
4.
Gombos R, Gonzalez A, Manrique M, Chand D, Savitsky D, Morin B, et al.
PLoS One
. 2018 Apr;
13(4):e0191926.
PMID: 29617360
CTLA-4 and CD28 exemplify a co-inhibitory and co-stimulatory signaling axis that dynamically sculpts the interaction of antigen-specific T cells with antigen-presenting cells. Anti-CTLA-4 antibodies enhance tumor-specific immunity through a variety...
5.
Breous-Nystrom E, Schultze K, Meier M, Flueck L, Holzer C, Boll M, et al.
Methods
. 2013 Sep;
65(1):57-67.
PMID: 24036249
Over the last nearly three decades in vitro display technologies have played an important role in the discovery and optimization of antibodies and other proteins for therapeutic applications. Here we...
6.
Polach K, Matar M, Rice J, Slobodkin G, Sparks J, Congo R, et al.
Mol Ther
. 2011 Oct;
20(1):91-100.
PMID: 21988874
We have designed a series of versatile lipopolyamines which are amenable to chemical modification for in vivo delivery of small interfering RNA (siRNA). This report focuses on one such lipopolyamine...